Navana Pharmaceuticals reported a 12% year-on-year profit growth in the July-September quarter of FY2024, reaching Tk 13.37 crore. Its earnings per share (EPS) increased to Tk 1.25 from Tk 1.11 in the same period last year, driven by strong sales and better material utilisation. Net sales jumped by 31% year-on-year to Tk 213.74 crore, according to the company’s unaudited financial statements.
Additionally, the company’s net operating cash flow per share (NOCFPS) surged to Tk 2, up from Tk 1.19, thanks to higher customer cash collections compared to vendor payments. Founded in 1992, Navana Pharmaceuticals operates two divisions: veterinary and human health. The veterinary division caters to the poultry, dairy, and aqua sectors, while the human health division manufactures a variety of products, including tablets, capsules, oral liquids, and eye drops. The company’s robust performance highlights its growing market presence.
Source for more details:
